Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 969
interventional 785
Observational 172
Registry 12

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 439
Biological 66
Biological|Drug 38
Drug|Other 21
Drug|placebo 21
Drug|Procedure 20
Radiation 20
Procedure 19
Biological|Drug|Other 16
Device 15
Other 15
Drug|Radiation 12
Biological|Drug|Procedure 9
Biological|Other 8
Behavioral 7
Biological|Drug|Other|Procedure|Radiation 5
Biological|Other|Procedure 5
Biological|placebo 5
Drug|Other|Procedure 5
Biological|Procedure 4
Diagnostic Test 4
Behavioral|Drug 2
Device|Drug 2
Drug|Other|placebo 2
Drug|Procedure|Radiation 2
Other|Procedure|Radiation 2
Procedure|Radiation 2
Behavioral|Dietary Supplement 1
Behavioral|Drug|Procedure 1
Behavioral|Other|Procedure 1
Biological|Device 1
Biological|Dietary Supplement 1
Biological|Drug|Other|placebo 1
Biological|Drug|Other|Procedure 1
Biological|Drug|placebo 1
Biological|Drug|Procedure|Radiation 1
Biological|Radiation 1
Combination Product 1
Device|Drug|Procedure 1
Diagnostic Test|Drug 1
Dietary Supplement|Drug|Other 1
Drug|Genetic|Other|Procedure 1
Drug|Other|Procedure|Radiation 1
Drug|Other|Radiation 1
Other|Procedure 1
Other|Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 418
France 27
Canada 22
China 20
United States|Canada 20
NA 18
Russian Federation 13
Netherlands 12
Germany 10
Italy 10
United Kingdom 10
Japan 8
Australia 7
Spain 6
Korea, Republic of 5
Denmark 4
Belgium 3
Israel 3
Sweden 3
Switzerland 3
United States|Australia 3
United States|Netherlands 3
United States|United Kingdom 3
Saudi Arabia 2
United States|Australia|Peru|Puerto Rico 2
United States|Canada|United Kingdom 2
United States|France 2
United States|France|Spain 2
United States|Germany 2
United States|Germany|Italy 2
United States|Peru 2
United States|Puerto Rico 2
Algeria|Egypt|India|Jordan|Lebanon|Russian Federation|Saudi Arabia|South Africa|Thailand|Tunisia 1
Argentina|Australia|Austria|Brazil|Chile|China|Czech Republic|Estonia|Greece|Hong Kong|India|Ireland|Italy|Korea, Republic of|Latvia|Lithuania|Mexico|New Zealand|Pakistan|Poland|Russian Federation|Slovakia|Tunisia|Ukraine|United Kingdom 1
Argentina|Australia|Austria|Brazil|Chile|China|Czech Republic|Estonia|Italy|Korea, Republic of|Latvia|Lithuania|New Zealand|Pakistan|Poland|Russian Federation|Slovakia|Tunisia|Ukraine|United Kingdom 1
Argentina|Australia|Brazil|Korea, Republic of|Mexico|Taiwan 1
Australia|Belgium|Czech Republic|Finland|France|Germany|Hungary|Israel|Italy|Netherlands|Norway|Poland|Russian Federation|Singapore|Spain|Switzerland|Taiwan|United Kingdom 1
Australia|Belgium|France|Netherlands|Turkey 1
Australia|New Zealand 1
Austria 1
Austria|Belgium|Czechia|France|Germany|Italy|Spain|United Kingdom 1
Austria|Belgium|Hungary|Israel|Italy|Netherlands|Turkey|United Kingdom 1
Austria|Bulgaria|Germany|Hungary|Poland|Romania|Slovakia|Spain|Switzerland|United Kingdom 1
Austria|France|Germany 1
Austria|France|Italy|Poland 1
Austria|Germany 1
Austria|Germany|Netherlands 1
Belgium|Canada|France|Spain|United Kingdom 1
Belgium|Czechia|France|Germany|Netherlands|Spain|United Kingdom 1
Belgium|Denmark|France|Germany|Italy|Netherlands|Poland|Spain|Sweden|Switzerland|United Kingdom 1
Belgium|France|Germany|Italy|Netherlands|Norway|Poland|Slovakia|Slovenia|United Kingdom 1
Belgium|France|Germany|Italy|Poland|Spain 1
Belgium|Germany|Netherlands|Slovakia 1
Belgium|Hungary|Italy|Netherlands|Norway|Russian Federation|Switzerland|Turkey|United Kingdom 1
Brazil 1
Bulgaria|Canada|India|Russian Federation|Slovakia|South Africa|Spain 1
Bulgaria|Romania|Russian Federation|Ukraine|United Kingdom 1
Chile 1
China|Japan|Korea, Republic of 1
China|Korea, Republic of|Taiwan 1
China|Taiwan 1
Czech Republic|Estonia|Finland|Germany|Greece|Italy|Lithuania|Netherlands|Russian Federation|Sweden|Switzerland|United Kingdom 1
Czech Republic|France|Netherlands|United Kingdom 1
Egypt 1
Finland|France|Germany|Italy|United Kingdom 1
France|Germany|Italy|Poland|United Kingdom 1
Germany|Netherlands 1
Hong Kong|United States|Belgium|Brazil|Czech Republic|Egypt|France|Germany|Hungary|Italy|Korea, Republic of|Netherlands|Russian Federation|Singapore|South Africa|Spain|Switzerland|Taiwan|Thailand|Turkey|United Kingdom 1
Hungary|Poland|Romania|Ukraine|United Kingdom 1
Hungary|United States|Austria|France|Italy|Poland|Romania|Spain 1
India 1
India|Russian Federation|Ukraine 1
Ireland|Sweden 1
Italy|United States|Netherlands|Spain 1
Japan|United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Colombia|Czech Republic|France|Germany|Greece|Hungary|Israel|Italy|Korea, Republic of|Netherlands|Norway|Poland|Saudi Arabia|Slovakia|Spain|Sweden|Switzerland|Thailand|United Kingdom 1
Japan|United States|Australia|Austria|Belgium|Canada|Denmark|France|Germany|Hungary|Israel|Italy|Korea, Republic of|Mexico|Netherlands|New Zealand|Romania|Russian Federation|Spain|Sweden|United Kingdom 1
Japan|United States|Australia|Bosnia and Herzegovina|Brazil|Canada|Czechia|Denmark|France|Germany|Italy|Korea, Republic of|Mexico|Poland|Russian Federation|Singapore|Spain|Taiwan|Thailand|Turkey|United Kingdom 1
Netherlands|United Kingdom 1
New Zealand|United Kingdom 1
Norway 1
Poland 1
Singapore 1
South Africa|United States|Argentina|Australia|Belgium|Brazil|Canada|Chile|Colombia|Czech Republic|France|Germany|Hong Kong|Hungary|India|Italy|Korea, Republic of|Malaysia|Mexico|Netherlands|Poland|Portugal|Russian Federation|Serbia|Singapore|Slovakia|Spain|Taiwan|Ukraine|United Kingdom 1
Taiwan 1
Thailand 1
Ukraine|United States|Argentina|Australia|Belgium|Brazil|Canada|Chile|France|Germany|Hungary|Israel|Italy|Netherlands|Poland|Russian Federation|South Africa|Spain|United Kingdom 1
United Kingdom|United States|Argentina|Australia|Brazil|Chile|Czechia|Germany|Greece|Israel|Italy|Japan|Mexico|Poland|Romania|Russian Federation|Spain|Turkey 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|China|Colombia|Czechia|France|Germany|Italy|Japan|Mexico|Netherlands|Poland|Romania|Russian Federation|Singapore|Spain|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|China|Czechia|Denmark|France|Germany|Ireland|Israel|Italy|Japan|Korea, Republic of|Netherlands|Poland|Russian Federation|Serbia|Spain|Taiwan|Thailand|Turkey|Ukraine|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|Colombia|Czechia|Denmark|Finland|France|Germany|Hungary|Ireland|Israel|Italy|Japan|Korea, Republic of|Mexico|Netherlands|Poland|Spain|Sweden|Taiwan|Turkey|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Chile|Czechia|Finland|France|Germany|Hong Kong|Hungary|Israel|Italy|Korea, Republic of|Mexico|Netherlands|New Zealand|Poland|Singapore|Spain|Taiwan|United Kingdom 1
United States|Argentina|Australia|Austria|Belgium|Brazil|Canada|Czechia|Denmark|Finland|France|Germany|Greece|Ireland|Israel|Italy|Japan|Norway|Poland|Romania|Russian Federation|Spain|Sweden|United Kingdom 1
United States|Argentina|Australia|Austria|Canada|Chile|China|Denmark|Finland|France|Germany|Hungary|Italy|Korea, Republic of|Netherlands|Singapore|Spain|Sweden|Switzerland|United Kingdom 1
United States|Argentina|Australia|Belgium|Brazil|Canada|Colombia|France|Germany|Hong Kong|Korea, Republic of|Mexico|Philippines|Singapore|Spain|Taiwan|United Kingdom 1
United States|Argentina|Australia|Brazil|Canada|Chile|Colombia|Czechia|Finland|France|Germany|Ireland|Italy|Japan|Korea, Republic of|Netherlands|Poland|Russian Federation|Spain|Taiwan|United Kingdom 1
United States|Argentina|Australia|Brazil|Chile|China|Colombia|Hong Kong|Mexico|New Zealand|Peru|Russian Federation|Singapore 1
United States|Argentina|Australia|Canada|Czech Republic|Former Serbia and Montenegro|Germany|Greece|Hungary|Italy|Latvia|Lithuania|Mexico|Netherlands|Poland|Russian Federation|Serbia|Slovakia|South Africa|Spain|Sweden|Taiwan|Turkey|Ukraine|United Kingdom| 1
United States|Argentina|Austria|Canada|Chile|Czechia|France|Germany|Hungary|Spain|United Kingdom 1
United States|Argentina|Austria|Chile|Czechia|France|Greece|Italy|Mexico|Poland|Portugal|Romania|Russian Federation|Spain 1
United States|Argentina|Brazil|Bulgaria|China|Russian Federation 1
United States|Argentina|Brazil|Canada 1
United States|Argentina|Bulgaria|Canada|Chile|Czechia|France|Hungary|India|Italy|Poland|Romania|Russian Federation|Serbia|Ukraine|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Chile|Czechia|Germany|Hong Kong|Israel|Italy|Japan|Korea, Republic of|Singapore|Spain|Taiwan|United Kingdom 1
United States|Australia|Austria|Belgium|Canada|Czechia|France|Germany|Greece|Ireland|Israel|Italy|Japan|Korea, Republic of|Netherlands|Poland|Russian Federation|Spain|Switzerland|United Kingdom 1
United States|Australia|Austria|Belgium|Czechia|France|Germany|Italy|Japan|Netherlands|Singapore|Spain|Switzerland|Taiwan 1
United States|Australia|Austria|Brazil|Canada|China|France|Germany|Greece|India|Ireland|Italy|Japan|Korea, Republic of|Poland|Russian Federation|Singapore|Slovakia|Spain|Sweden|Taiwan|United Kingdom 1
United States|Australia|Austria|Canada|Israel|Italy 1
United States|Australia|Belgium|China|Czech Republic|Hong Kong|Israel|Taiwan 1
United States|Australia|Brazil|Canada|Chile|France|Germany|Hungary|Ireland|Italy|Japan|Korea, Republic of|New Zealand|Norway|Russian Federation|Spain|Taiwan|Turkey|Ukraine|United Kingdom 1
United States|Australia|Brazil|Canada|France|Germany|Italy|Poland|Russian Federation|Spain|United Kingdom 1
United States|Australia|Canada 1
United States|Australia|Canada|China|Germany|Ireland|Italy|Japan|Korea, Republic of|Netherlands|Spain|Sweden|Taiwan|United Kingdom 1
United States|Australia|Canada|Czechia|Finland|Greece|Italy|Korea, Republic of|Netherlands|Poland|Portugal|Romania|Russian Federation|Spain|Taiwan|United Kingdom 1
United States|Australia|Canada|France|Germany|Italy|Japan|Netherlands|Poland|Spain 1
United States|Australia|Canada|France|Netherlands|United Kingdom 1
United States|Australia|Canada|Japan|Singapore|Spain|United Kingdom 1
United States|Australia|Canada|Netherlands|New Zealand|Puerto Rico|Switzerland 1
United States|Australia|Canada|New Zealand|Puerto Rico 1
United States|Australia|Chile 1
United States|Australia|France|Germany|Italy|New Zealand|Spain|United Kingdom 1
United States|Australia|France|Italy|Japan 1
United States|Australia|Korea, Republic of 1
United States|Australia|Singapore 1
United States|Australia|Taiwan 1
United States|Austria|Belgium|Canada|France|Israel|Norway|Poland|Spain|Sweden|United Kingdom 1
United States|Belgium|Canada|Czechia|Denmark|France|Germany|Hungary|Italy|Poland|Spain|United Kingdom 1
United States|Belgium|Canada|France|Italy|Poland|Spain|United Kingdom 1
United States|Belgium|France|Germany|Italy|Spain|United Kingdom 1
United States|Belgium|France|Italy|New Zealand|Spain|United Kingdom 1
United States|Brazil|France|Italy|Korea, Republic of|Russian Federation|Ukraine 1
United States|Bulgaria|Canada|Chile|Czech Republic|France|Hungary|India|Italy|Poland|Romania|Russian Federation|Serbia|Ukraine|United Kingdom 1
United States|Canada|Czechia|France|Italy|Poland|Spain|United Kingdom 1
United States|Canada|Denmark|France|Germany|Italy|Korea, Republic of|Spain|United Kingdom 1
United States|Canada|Finland|Italy 1
United States|Canada|France|Germany|Netherlands|United Kingdom 1
United States|Canada|Israel 1
United States|Canada|Puerto Rico 1
United States|Canada|Spain|United Kingdom 1
United States|Chile|Colombia|Finland|Korea, Republic of|Norway|Russian Federation|Spain|Turkey|Ukraine 1
United States|China|Bosnia and Herzegovina|Bulgaria|Chile|India|Malaysia|Mexico|Philippines|Romania|Russian Federation|South Africa|Taiwan|Ukraine 1
United States|Czechia|France|Germany|Italy|Poland|Romania|Spain|United Kingdom 1
United States|Czechia|France|Hungary|Latvia|Poland|Spain|Sweden|United Kingdom 1
United States|Czechia|Germany|Japan|Russian Federation|Spain 1
United States|Czechia|Hungary|United Kingdom 1
United States|Czechia|Poland|Spain|United Kingdom 1
United States|Denmark|France|United Kingdom 1
United States|Finland|France|Germany|Poland|United Kingdom 1
United States|France|Germany 1
United States|France|Germany|Greece|Netherlands|Sweden|Switzerland 1
United States|France|Germany|Hong Kong|Hungary|Italy|Netherlands|Spain|United Kingdom 1
United States|France|Germany|Hungary|Italy|Netherlands|Norway|Poland|Romania|Russian Federation|United Kingdom 1
United States|France|Germany|Israel|Poland|Romania|Russian Federation|Spain|Ukraine|United Kingdom 1
United States|France|Germany|Netherlands|Spain|Taiwan 1
United States|France|Germany|Poland|Russian Federation|Ukraine|United Kingdom 1
United States|France|Germany|Spain|United Kingdom 1
United States|France|Singapore|United Kingdom 1
United States|Germany|Korea, Republic of|Netherlands|Spain|Taiwan|United Kingdom 1
United States|Italy 1
United States|Italy|Korea, Republic of|Poland|Spain 1
United States|Italy|Taiwan|United Kingdom 1
United States|Italy|United Kingdom 1
United States|Japan|United Kingdom 1
United States|Korea, Republic of 1
United States|Korea, Republic of|Spain|United Kingdom 1
United States|Puerto Rico|South Africa 1
United States|Singapore 1
United States|Spain|United Kingdom 1
United States|United Kingdom|Argentina|Australia|Brazil|Canada|Denmark|France|Germany|Hong Kong|Italy|Korea, Republic of|Mexico|Netherlands|Peru|Spain|Taiwan|Thailand|Turkey 1

Sites per Study

Site_count Study_Count
1 356
2 58
3 32
4 28
5 27
6 12
7 13
8 20
9 9
10 18
11 14
12 12
13 10
14 10
15 6
16 1
17 8
18 6
19 7
20 3
21 4
22 4
23 2
24 4
25 8
26 3
27 2
28 3
29 2
30 1
32 1
33 1
34 2
35 3
36 3
37 1
38 3
39 3
40 1
41 2
42 2
43 1
44 1
45 2
49 1
50 2
51 3
52 1
55 2
56 1
57 1
58 1
60 1
61 1
65 1
72 1
75 1
76 1
84 1
86 1
92 1
93 2
95 1
99 1
100 1
101 1
104 1
106 1
108 2
113 1
119 1
121 1
124 1
125 1
128 1
133 1
134 1
141 1
143 1
152 1
154 2
156 1
159 1
172 1
177 1
186 2
187 1
189 1
191 1
199 1
204 1
205 1
214 1
225 1
227 1
234 1
235 1
251 1
282 1
294 1
320 1
374 1
488 1
493 1
508 1
559 1
587 1
597 1
721 1
987 1
1003 1
1329 1

Phase

Phase Study_Count
Phase 2 341
Phase 1 162
Phase 1/Phase 2 97
Phase 3 75
N/A 71
Phase 4 18
Early Phase 1 16
Phase 2/Phase 3 5

Number of Arms

Number_of_Arms Count_of_Studies
1 378
2 203
3 41
4 29
5 9
6 9
8 4
9 4
10 3
14 1
15 1
17 1
24 1
37 1
NA 100

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.2.Phase.3 Phase.3 Phase.4
Min. 2.0000 1.00 2.00000 4.00000 1.0000 9 15.0000 20.00000
1st Qu. 13.7500 17.75 19.00000 30.00000 26.0000 30 315.0000 44.00000
Median 18.0000 38.00 30.00000 55.00000 51.0000 120 600.0000 50.00000
Mean 25.0625 99.20 61.31847 97.52577 101.7962 215 701.4085 78.82353
3rd Qu. 30.0000 108.50 68.00000 99.00000 98.0000 390 875.0000 105.00000
Max. 105.0000 1000.00 395.00000 557.00000 6452.0000 526 3031.0000 200.00000

Trial Group Type

group_type Group_Count
Experimental 1103
Active Comparator 120
NA 100
Other 51
Placebo Comparator 27
No Intervention 25
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Single Group Assignment 449
Parallel Assignment 232
NA 67
Sequential Assignment 24
Crossover Assignment 9
Factorial Assignment 4

Primary Purpose

primary_purpose Study_Count
Treatment 705
Diagnostic 38
Supportive Care 13
Other 9
NA 7
Basic Science 6
Prevention 5
Device Feasibility 1
Health Services Research 1

Observational Studies

Studies by Country

Country Study_Count
United States 35
France 17
NA 15
Netherlands 11
Spain 9
Germany 8
Japan 8
Korea, Republic of 7
Canada 6
United Kingdom 6
China 5
Denmark 5
Italy 5
Belgium 3
Turkey 3
India 2
Singapore 2
Sweden 2
Algeria|Egypt 1
Argentina|Austria|China|Colombia|Czech Republic|France|Germany|Greece|Indonesia|Korea, Republic of|Mexico|Netherlands|Philippines|Poland|Russian Federation|Slovakia|Slovenia|Sweden 1
Argentina|Colombia 1
Austria|Belgium|Czechia|France|Germany|Greece|Italy|Netherlands|Poland|Spain|United Kingdom 1
Austria|Belgium|France|Germany|Greece|Italy|Netherlands|Poland|Romania 1
Austria|Belgium|France|Greece|Italy|Netherlands|Spain|United Kingdom 1
Austria|Germany 1
Brazil 1
Croatia 1
Czech Republic 1
Czechia|Poland 1
Finland 1
Greece 1
Israel 1
Israel|United States|Argentina|Austria|Belgium|Colombia|Estonia|Finland|Germany|Greece|Hungary|Italy|Lebanon|Pakistan|Spain|Taiwan|Turkey|United Kingdom 1
Norway 1
Poland 1
Romania 1
Russian Federation 1
Slovakia 1
Taiwan 1
United States|Denmark|Finland|Italy|Portugal|United Kingdom 1
United States|France|Germany 1

Sites per Study

Site_count Study_Count
1 120
2 9
3 4
4 3
5 2
6 2
7 2
8 4
10 1
12 1
13 1
14 3
16 2
18 2
19 1
21 2
27 1
34 1
37 1
40 1
41 1
45 1
50 1
57 1
75 1
108 1
110 1
118 1
144 1

Enrollment Metrics

Measure Observational
Min 1.00
1st Qu 50.00
Median 120.00
Mean 14633.85
3rd Qu 400.00
Max 2323608.00

Observation Model

observational_model Study_Count
Cohort 113
Case-Only 29
Other 12
Case-Control 9
NA 4
Case Control 3
Case-Crossover 1
Family-Based 1

Time Perspective

time_perspective Study_Count
Prospective 111
Retrospective 52
Cross-Sectional 6
Other 2
NA 1

Registries

Studies by Country

Country Study_Count
Denmark 3
United States 3
Germany 2
Italy 1
Korea, Republic of 1
Netherlands 1
Spain 1

Sites per Study

Site_count Study_Count
1 11
25 1

Enrollment Metrics

Measure Registries
Min 20.00
1st Qu 98.25
Median 750.00
Mean 1907.50
3rd Qu 1875.00
Max 10000.00

Registry Model

observational_model Study_Count
Cohort 9
Case-Only 2
Other 1

Time Perspective

time_perspective Study_Count
Prospective 10
Other 2

Follow-up

target_duration Study_Count
10 Years 2
3 Years 2
5 Years 2
1 Week 1
1 Year 1
3 Months 1
36 Months 1
6 Months 1
9 Months 1

Overview of Studies

Interventional Trials

#If less then 500 trials

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03409224 Differences in Immunologic Response to Cryoablation Versus Radiofrequency Ablation in the Treatment of Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT03409224 Active, not recruiting University of California, Irvine 2019-06-30
NCT03395379 Air Dissection in Percutaneous Radiofrequency Ablation of T1a Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT03395379 Completed Centre Hospitalier Universitaire de Nice 2016-03-15
NCT03293563 UroCCR Database: French Research Network for Kidney Cancer https://ClinicalTrials.gov/show/NCT03293563 Recruiting University Hospital, Bordeaux 2021-12-31
NCT03291028 Analysis of Primary and Metastatic Tumors in Patients With Renal Cell Carcinoma and Urothelial Carcinoma https://ClinicalTrials.gov/show/NCT03291028 Recruiting Fox Chase Cancer Center 2020-12-31
NCT03226886 TRACERx Renal (TRAcking Renal Cell Carcinoma Evolution Through Therapy (Rx)) https://ClinicalTrials.gov/show/NCT03226886 Recruiting Royal Marsden NHS Foundation Trust 2023-09-01
NCT03161145 A Study to Observe the Treatment Patterns and Outcomes of Patients in Japan With Kidney Cancer That is Unable to be Removed by Surgery or That Has Spread https://ClinicalTrials.gov/show/NCT03161145 Completed Bristol-Myers Squibb 2017-08-31
NCT03140176 Real-world Clinical Patterns Of Care And Outcomes Among AfME mRCC Patients Receiving Sunitinib as First Line Therapy. https://ClinicalTrials.gov/show/NCT03140176 Recruiting Pfizer 2020-12-30
NCT03133286 Radiotherapy Assessments During Intervention ANd Treatment (RADIANT) https://ClinicalTrials.gov/show/NCT03133286 Recruiting DxTerity Diagnostics 2019-09-06
NCT03097601 ELR+CXCL Cytokines in Metastatic Kidney Cancers: Predictive Markers of Resistance to Sunitinib https://ClinicalTrials.gov/show/NCT03097601 Active, not recruiting Centre Antoine Lacassagne 2019-12-30
NCT03091465 Validation of the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) Prognostic Classification for Targeted Therapies (TKI/mTOR Inhibitors) in Second Line After First Line Treatment With Pazopanib https://ClinicalTrials.gov/show/NCT03091465 Completed Spanish Oncology Genito-Urinary Group 2017-04-17
NCT03052504 Prospective Versus Retrospective Complications in Radical Cystectomy and Nephrectomy https://ClinicalTrials.gov/show/NCT03052504 Completed Aarhus University Hospital 2018-02-28
NCT02940639 Real-Life Efficacy and Safety of Nivolumab in Patients With Advanced/Metastatic Renal Cell Carcinoma After Prior Therapy https://ClinicalTrials.gov/show/NCT02940639 Recruiting Bristol-Myers Squibb 2024-10-31
NCT02923284 NANOTECH RCC Biomarkers https://ClinicalTrials.gov/show/NCT02923284 Completed Washington University School of Medicine 2020-01-02
NCT02848768 Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT02848768 Completed Rennes University Hospital 2015-03-31
NCT02809404 Dried Blood SPOT Analysis of Everolimus in Cancer Patients (SPOT-study) https://ClinicalTrials.gov/show/NCT02809404 Completed Radboud University 2016-01-31
NCT02776644 Clinical Outcome Of Advanced Renal Cell Carcinoma In Taiwan https://ClinicalTrials.gov/show/NCT02776644 Completed Pfizer 2017-12-30
NCT02732665 Glycosaminoglycan Scores as Monitoring Biomarkers in Advanced Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT02732665 Recruiting Chalmers University of Technology 2019-03-31
NCT02732652 Glycosaminoglycan Scores as Monitoring Biomarkers in Confined Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT02732652 Recruiting Chalmers University of Technology 2019-03-31
NCT02664883 Myeloid Derived Suppressor Cells Clinical Assay in Finding Kidney Cancer https://ClinicalTrials.gov/show/NCT02664883 Recruiting University of Southern California 2020-09-08
NCT02627144 Bevacizumab in Metastatic Renal Cancer https://ClinicalTrials.gov/show/NCT02627144 Completed Hoffmann-La Roche 2014-09-30
NCT00033137 Genetic Analysis of Birt Hogg-Dube Syndrome and Characterization of Predisposition to Kidney Cancer https://ClinicalTrials.gov/show/NCT00033137 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT04353765 Non - Interventional, Retrospective Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors https://ClinicalTrials.gov/show/NCT04353765 Recruiting Ipsen 2020-12-30
NCT00050752 Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer https://ClinicalTrials.gov/show/NCT00050752 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT03628859 BIOREN (Predictive BIOmarkers in Metastatic RENal Cancer) https://ClinicalTrials.gov/show/NCT03628859 Recruiting Centre Leon Berard 2023-06-30
NCT00001238 Clinical Manifestations and Molecular Bases of Heritable Urologic Malignant Disorders https://ClinicalTrials.gov/show/NCT00001238 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT02537743 Prospective Patient Reported Outcomes (PRO) Registry in Patients With Advanced Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT02537743 Active, not recruiting iOMEDICO AG 2020-12-31
NCT02499458 Prospective Validation of Circulating Tumor Cells & Circulating Endothelial Cells as Biomarkers in Renal Cancer https://ClinicalTrials.gov/show/NCT02499458 Completed Lawson Health Research Institute 2018-12-31
NCT02411968 Follow up After Cryoablation of Small Renal Masses. https://ClinicalTrials.gov/show/NCT02411968 Completed Radboud University 2018-09-30
NCT02370290 Quantitative Imaging Metrics From CECT in Measuring Disease Response or Progression in Patients With Kidney Cancer https://ClinicalTrials.gov/show/NCT02370290 Completed University of Southern California 2015-12-31
NCT02315755 Observational Study Evaluating The Efficacy And Effects On Quality Of Life Of Targeted Treatments Following TKIs In mRCC https://ClinicalTrials.gov/show/NCT02315755 Completed Pfizer 2017-11-20
NCT02247583 Investigating Patient Satisfaction With Oral Anti-Cancer Treatment https://ClinicalTrials.gov/show/NCT02247583 Completed KU Leuven 2013-07-31
NCT02228954 IMaging PAtients for Cancer Drug selecTion - Renal Cell Carcinoma (IMPACT-RCC) https://ClinicalTrials.gov/show/NCT02228954 Active, not recruiting Radboud University 2018-03-05
NCT02187042 Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line https://ClinicalTrials.gov/show/NCT02187042 Completed Pfizer 2018-07-25
NCT02186925 A Prospective Study of Clinical Factors Affecting Disease Progression and Treatment Results of Patients With Tumors of the Prostate, Bladder and Kidney. https://ClinicalTrials.gov/show/NCT02186925 Recruiting Meir Medical Center 2019-08-31
NCT02184416 Study Of The Impact Of Inlyta In 2nd Line On The Treatment Outcomes Of mRCC Patients Treated With Sutent In 1st Line In The Real Life Setting https://ClinicalTrials.gov/show/NCT02184416 Recruiting Pfizer 2021-05-01
NCT02156895 Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea https://ClinicalTrials.gov/show/NCT02156895 Recruiting Pfizer 2021-08-21
NCT02150369 Interleukin-2—Induced Cognitive/Affective/Sleep Symptoms https://ClinicalTrials.gov/show/NCT02150369 Completed Duke University 2017-03-02
NCT02143492 Tumor Collection From Routine Nephrectomy for Subjects With Advanced Stage RCC https://ClinicalTrials.gov/show/NCT02143492 Completed Argos Therapeutics 2015-07-31
NCT02121730 Identification of Risk Factors Associated With Neoplastic Complications After Renal Transplantation in Nord-Pas de Calais , Normandy and Picardy Regions https://ClinicalTrials.gov/show/NCT02121730 Recruiting Centre Hospitalier Universitaire, Amiens 2019-08-31
NCT02086734 Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients With Metastasized Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT02086734 Completed Ludwig-Maximilians - University of Munich 2018-07-31
NCT02087852 Kidney Cancer DNA Registry https://ClinicalTrials.gov/show/NCT02087852 Recruiting Memorial Sloan Kettering Cancer Center 2021-03-31
NCT01773655 Clinical and Histopathologic Characteristics of BAP1 Mutations https://ClinicalTrials.gov/show/NCT01773655 Completed Memorial Sloan Kettering Cancer Center 2020-06-30
NCT01931644 At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions https://ClinicalTrials.gov/show/NCT01931644 Recruiting Sanguine Biosciences 2025-08-31
NCT01917214 A Retrospective Real World Analysis Of Sutent In Patients With Metastatic Renal Cell Carcinoma In Community And Academic Centers To Assess The Impact Of Dose Variation On Duration Of Response And Overall Survival https://ClinicalTrials.gov/show/NCT01917214 Completed Pfizer 2014-03-31
NCT01827254 Sutent Rechallenge In mRCC Patients https://ClinicalTrials.gov/show/NCT01827254 Completed Pfizer 2014-04-30
NCT01728948 Sorafenib in Elderly mRCC https://ClinicalTrials.gov/show/NCT01728948 Completed Bayer 2016-01-04
NCT01649778 Observational Study of Real World Effectiveness Data and Safety in Patients Receiving Pazopanib With Advanced or Metastatic Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT01649778 Completed Novartis 2017-07-03
NCT01598597 An Observational Pilot Study Evaluating the Feasibility of Conducting Genome-Wide Association Studies Utilizing Subject Provided Information in Subjects With Locally Recurrent or MBC, MCRC, MNSCLC, RGBM or MRCC Treated With Avastin (Bevacizumab) (InVite) https://ClinicalTrials.gov/show/NCT01598597 Completed Genentech, Inc. 2014-11-30
NCT01585974 Duration of Treatment With Tyrosine Kinase Inhibitors in the Treatment of Metastatic Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT01585974 Completed Bayer 2015-06-30
NCT01538823 Urine Proteome of Surgical Patients and Healthy Volunteers https://ClinicalTrials.gov/show/NCT01538823 Completed Washington University School of Medicine 2016-07-31
NCT01508364 Nexavar as First Targeted Therapy in Patients With Advanced Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT01508364 Completed Bayer 2013-12-31
NCT01482520 Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT01482520 Completed Samsung Medical Center 2013-09-30
NCT01447199 The Molecular Predisposition to Hereditary Nonpolyposis Colon Cancer (HNPCC) https://ClinicalTrials.gov/show/NCT01447199 Active, not recruiting M.D. Anderson Cancer Center 2020-09-30
NCT01449825 Hepatic Monitoring for Pazopanib https://ClinicalTrials.gov/show/NCT01449825 Completed GlaxoSmithKline 2013-12-31
NCT01446224 Cardiovascular and Torsades de Pointes Monitoring for Pazopanib https://ClinicalTrials.gov/show/NCT01446224 Completed GlaxoSmithKline 2013-12-31
NCT01444456 Assessment of Quality of Life in Patients With Symptomatic Chemotherapy-induced Anaemia https://ClinicalTrials.gov/show/NCT01444456 Completed Amgen 2013-08-31
NCT01415167 PROCLAIM Registry to Evaluate the Treatment Patterns and Clinical Response in Malignancy https://ClinicalTrials.gov/show/NCT01415167 Completed Prometheus Laboratories 2018-04-30
NCT01441661 Sunitinib Intake Conditions in the Treatment of Patients With Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT01441661 Completed Cancer Foundation, China 2012-06-30
NCT01412671 Nexavar Post-marketing Surveillance for RCC in Japan: Early Access Program https://ClinicalTrials.gov/show/NCT01412671 Completed Bayer 2011-09-21
NCT01405183 Association Between Hepatitis C Infection and Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT01405183 Completed Henry Ford Health System 2013-08-31
NCT01398306 Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours. https://ClinicalTrials.gov/show/NCT01398306 Completed University Medical Center Groningen 2012-04-30
NCT01392729 An Observational Study of Avastin (Bevacizumab) and Interferon Alpha 2a in Patients With Metastatic Renal Cell Cancer (VERA) https://ClinicalTrials.gov/show/NCT01392729 Completed Hoffmann-La Roche 2015-06-30
NCT01390519 A Norwegian Observational Trial Evaluating the Treatment of Advanced Renal Cell Cancer Patients Under Treatment of Afinitor https://ClinicalTrials.gov/show/NCT01390519 Completed Novartis 2015-12-31
NCT01381614 Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (IHCIS) https://ClinicalTrials.gov/show/NCT01381614 Completed GlaxoSmithKline 2011-12-31
NCT01381601 Incidence, Prevalence, and Symptom Burden Associated With Advanced Renal Cell Carcinoma in Commercially Insured Population (Pharmetrics) https://ClinicalTrials.gov/show/NCT01381601 Completed GlaxoSmithKline 2011-10-31
NCT01367457 INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus https://ClinicalTrials.gov/show/NCT01367457 Completed Pfizer 2015-04-30
NCT01370109 Cardiovascular Effects of Sunitinib Therapy (CREST) https://ClinicalTrials.gov/show/NCT01370109 Completed Abramson Cancer Center of the University of Pennsylvania 2017-12-31
NCT01351571 An Observational Study of Avastin (Bevacizumab) in Combination With Interferon Alpha-2a as First-Line Treatment in Patients With Advanced and/or Metastatic Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT01351571 Completed Hoffmann-La Roche 2011-08-31
NCT01339975 Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT01339975 Completed University Hospital, Bordeaux 2014-05-31
NCT01339962 Retrospective Analysis Of Progression Free Survival And Overall Survival In A National Cohort Of Patients With Metastatic Renal Cell Carcinoma Treated In Denmark From 2006-2010. DARENCA Study 2. https://ClinicalTrials.gov/show/NCT01339962 Completed Pfizer 2012-04-30
NCT01328691 Prognostic Factor for Renal Cell Carcinoma (RCC) With Venous Tumor Thrombus https://ClinicalTrials.gov/show/NCT01328691 Completed Seoul National University Hospital 2011-03-31
NCT04416646 Cabozantinib in the Elderly With Metastatic Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT04416646 Recruiting Istituto Oncologico Veneto IRCCS 2020-06-27
NCT04415697 Identification of Predictive Gene Expression Profile of Sunitinib Response in Metastatic Clear Cell Renal Carcinomas https://ClinicalTrials.gov/show/NCT04415697 Completed Barretos Cancer Hospital 2020-02-20
NCT04392076 Image Guided RFA/MWA/CRYO of RCC Biomarker Profile Study https://ClinicalTrials.gov/show/NCT04392076 Recruiting University of Leeds 2020-12-31
NCT04377113 Cellular Immunity and Renal Cell Cancer https://ClinicalTrials.gov/show/NCT04377113 Recruiting Clinical Hospital Center Rijeka 2020-12-31
NCT04368546 Sunitinib Treatment on Tissue Sodium Accumulation (TSS2) https://ClinicalTrials.gov/show/NCT04368546 Active, not recruiting Charite University, Berlin, Germany 2019-02-01
NCT04375150 Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC https://ClinicalTrials.gov/show/NCT04375150 Active, not recruiting Pfizer 2021-03-02
NCT04350047 Renal Cell Carcinoma and Stage IV Inferior Vena Cava Thrombus: Resection Without Thoracotomy https://ClinicalTrials.gov/show/NCT04350047 Completed Attikon Hospital 2020-03-31
NCT04309617 Retrospective Study on Referral Patterns for High Risk Patients Post Nephrectomy https://ClinicalTrials.gov/show/NCT04309617 Recruiting Pfizer 2020-04-15
NCT04268368 Immune Related-adverse Events in Patients Receiving Immune Checkpoint Inhibitors https://ClinicalTrials.gov/show/NCT04268368 Recruiting Università Politecnica delle Marche 2021-01-01
NCT04245410 Surgical Treatment of Pancreatic Metastases From Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT04245410 Recruiting Universidad de Extremadura 2020-03-01
NCT04222374 Uro-DNA Collection for Expanded Genome-Wide Association Study (GWAS) of Renal Cell Carcinoma (RCC) https://ClinicalTrials.gov/show/NCT04222374 Recruiting University Hospital, Bordeaux 2020-04-30
NCT04213664 Meta-analysis of the Prognostic Value of Lymphocyte to Monocyte Ratio (LMR) in Non-metastatic Renal Cell Carcinoma. https://ClinicalTrials.gov/show/NCT04213664 Recruiting Corporacion Parc Tauli 2020-01-02
NCT04213157 Laparoscopic Partial Nephrectomy for cT1 Tumors https://ClinicalTrials.gov/show/NCT04213157 Completed Samsun Liv Hospital 2019-08-30
NCT04175262 Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments https://ClinicalTrials.gov/show/NCT04175262 Completed Pfizer 2020-03-09
NCT04154163 Appropriate Dosing to Optimise Personalised Cancer Treatments https://ClinicalTrials.gov/show/NCT04154163 Recruiting University of Dundee 2020-07-30
NCT04147143 CaboCHECK - Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional Study https://ClinicalTrials.gov/show/NCT04147143 Recruiting Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest 2020-03-08
NCT04113486 Expression Levels of Nicotinamide Metabolism-related Protein (NMAP) in Newly Diagnosed Renal Cancer and Non-renal Cancer Populations https://ClinicalTrials.gov/show/NCT04113486 Recruiting Xinhua Hospital, Shanghai Jiao Tong University School of Medicine 2021-09-30
NCT04106349 Observational Real-life Study of Cabozantinib in Advanced Renal Cell Carcinoma (RCC) https://ClinicalTrials.gov/show/NCT04106349 Recruiting Ipsen 2023-01-30
NCT04115189 A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With mRCC in Latin America (LA) https://ClinicalTrials.gov/show/NCT04115189 Recruiting Pfizer 2020-04-30
NCT04076787 Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib https://ClinicalTrials.gov/show/NCT04076787 Completed Pfizer 2018-09-02
NCT04053855 Evaluation of Urinary Exosomes Presence From Clear Cell Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT04053855 Recruiting Centre Hospitalier Universitaire de Saint Etienne 2021-09-30
NCT04043975 A Prospective Observational Study of Renal Cell Cancer Patients Treated With Nivolumab Plus Ipilimumab in the Real World Setting in Japan https://ClinicalTrials.gov/show/NCT04043975 Recruiting Bristol-Myers Squibb 2022-08-01
NCT04040530 Patient Reported Outcome After Nephron Sparing Treatment of Small Renal Tumours https://ClinicalTrials.gov/show/NCT04040530 Recruiting Region of Southern Denmark 2021-09-01
NCT04033991 Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib. https://ClinicalTrials.gov/show/NCT04033991 Active, not recruiting Pfizer 2020-05-31
NCT04006405 AURORAX-087A: GAG Scores for Surveillance of Recurrence in Leibovich Points ≥5 Non-metastatic ccRCC https://ClinicalTrials.gov/show/NCT04006405 Recruiting Elypta 2022-02-28
NCT03981497 Microwave Ablation for Treatment of Small Renal Tumors and Primary and Secondary Liver Neoplasms https://ClinicalTrials.gov/show/NCT03981497 Recruiting IRCCS San Raffaele 2024-02-28
NCT03928964 MEtatastic Renal Carcinoma LINes https://ClinicalTrials.gov/show/NCT03928964 Active, not recruiting Centre Hospitalier Universitaire de Besancon 2018-10-03
NCT03916458 REGISTRY OF COMPLETE RESPONSES TO SUNITINIB IN SPANISH PATIENTS WITH METASTATIC RENAL CELL CARCINOMA https://ClinicalTrials.gov/show/NCT03916458 Recruiting Pfizer 2020-09-30
NCT03891485 Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy https://ClinicalTrials.gov/show/NCT03891485 Recruiting National Cancer Institute, Naples 2020-12-31
NCT03896958 The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology) https://ClinicalTrials.gov/show/NCT03896958 Recruiting SpeciCare 2021-03-12
NCT03776123 Post Marketing Surveillance to Observe Safety and Effectiveness of CABOMETYXâ„¢ in Korea. https://ClinicalTrials.gov/show/NCT03776123 Recruiting Ipsen 2022-02-28
NCT03748901 PD-L1 Expression in Japanese Renal Cell Carcinoma Patients https://ClinicalTrials.gov/show/NCT03748901 Active, not recruiting Chugai Pharmaceutical 2019-12-31
NCT03744585 Cabozantinib Real-life Use for Advanced Renal Cell Carcinoma in France: a Retrospective Descriptive Non-interventional Study of 2 Cohorts. https://ClinicalTrials.gov/show/NCT03744585 Completed Ipsen 2019-06-07
NCT03728842 Spontaneous Regression in Metastatic Melanoma and Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT03728842 Recruiting Indiana University 2021-03-01
NCT03734614 Preventive Effects of Aspirin as Adjuvant Therapy in Patients With Locally Advanced Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT03734614 Recruiting RenJi Hospital 2024-10-31
NCT03696407 A Non-interventional Retrospective Study to Describe Early Clinical Experience With Cabozantinib in Patients With Advanced Renal Cell Carcinoma (RCC) in the UK https://ClinicalTrials.gov/show/NCT03696407 Completed Ipsen 2019-08-01
NCT03699579 Pharmaco-Economic Study of Treatment Options in Patients With Advanced RCC https://ClinicalTrials.gov/show/NCT03699579 Completed Ipsen 2019-06-23
NCT03694912 Development and Evaluation of High Risk Group Prediction Model in T1 Stage Renal Cell Cancer Using Molecular Biomarkers https://ClinicalTrials.gov/show/NCT03694912 Recruiting Yonsei University 2023-09-22
NCT03670992 Surgical Treatment of Pancreatic RCC Metastases https://ClinicalTrials.gov/show/NCT03670992 Completed Azienda Policlinico Umberto I 2017-01-10
NCT03647878 Study of Cabozantinib in Patients With Advanced or Metastatic Renal Cell Carcinoma Under Real-life Clinical Setting in 1st Line Treatment. https://ClinicalTrials.gov/show/NCT03647878 Recruiting Ipsen 2022-08-30
NCT03663946 A Study to Observe the Onset of Immune-related Adverse Reactions in Patients With Non-surgical or Renal Cell Carcinoma (RCC) That Has Spread https://ClinicalTrials.gov/show/NCT03663946 Recruiting Bristol-Myers Squibb 2021-12-31
NCT02850809 Evaluation of the Efficacy of Radiofrequency in the Treatment of Renal Tumors https://ClinicalTrials.gov/show/NCT02850809 Completed University Hospital, Bordeaux 2015-12-31
NCT03630692 Safety and Compliance of Renal Cancer Patients Treated by Non-IV Drugs https://ClinicalTrials.gov/show/NCT03630692 Recruiting Institut Cancerologie de l’Ouest 2020-01-31
NCT03568435 Safety and Effectiveness of Nivolumab in Recurring Kidney Cancer Participants https://ClinicalTrials.gov/show/NCT03568435 Active, not recruiting Bristol-Myers Squibb 2020-12-31
NCT03538717 “Retrospective Study to Identify Clinical Factors Related to a High Benefit of Axitinib in mRCC” https://ClinicalTrials.gov/show/NCT03538717 Completed Pfizer 2019-03-01
NCT03519542 Epidemiological Study to Identify Prognosis and Predictive Biomarkers for Advanced or Metastatic Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT03519542 Completed Spanish Oncology Genito-Urinary Group 2016-12-31
NCT03471897 Plasma Glycosaminoglycans as Diagnostic and Prognostic Biomarkers in Surgically Treated Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT03471897 Completed Chalmers University of Technology 2017-10-25
NCT03455452 An Observational Study of Nivolumab in Participants With Advanced Kidney Cancer https://ClinicalTrials.gov/show/NCT03455452 Recruiting Bristol-Myers Squibb 2022-01-18
NCT03414827 Genetic Evaluation of Renal Cell Carcinoma; Predicting Biomarkers for Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT03414827 Recruiting Zealand University Hospital 2020-12-01
NCT01246843 Evaluation of Cognitive Function of Patients With Sunitinib or Sorafenib https://ClinicalTrials.gov/show/NCT01246843 Completed Radboud University 2011-04-30
NCT01227213 The Vascular and Metabolic Effects of Sunitinib in Patients With Metastatic Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT01227213 Completed Radboud University 2013-11-30
NCT01236053 Cancer in Patients With Gabapentin (GPRD) https://ClinicalTrials.gov/show/NCT01236053 Completed GlaxoSmithKline 2010-09-30
NCT01210482 Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan) https://ClinicalTrials.gov/show/NCT01210482 Completed Pfizer 2018-03-31
NCT01173445 Circulating Tumors Cells and Circulating Endothelial Cells in Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT01173445 Completed University of Kansas Medical Center 2011-05-31
NCT01138124 Gabapentin and Risk of Pancreatic Cancer and Renal Cancer (GPRD) https://ClinicalTrials.gov/show/NCT01138124 Completed GlaxoSmithKline 2010-08-31
NCT01135849 B-Receptor Signaling in Cardiomyopathy https://ClinicalTrials.gov/show/NCT01135849 Completed Stanford University 2010-10-31
NCT01087060 Detection of Renal Malignancy of Complicated Renal Cysts https://ClinicalTrials.gov/show/NCT01087060 Completed Seoul National University Hospital 2008-03-31
NCT01056263 Retrospective Observational Study To Update 5-Year Survival Of Subjects Who Participated In Axitinib Trial A4061012 https://ClinicalTrials.gov/show/NCT01056263 Completed Pfizer 2010-12-31
NCT01026337 Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer https://ClinicalTrials.gov/show/NCT01026337 Completed Abramson Cancer Center of the University of Pennsylvania 2015-12-31
NCT01028638 Vascular Endothelial Growth Factor (VEGF) Imaging Before and During Everolimus Treatment for Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT01028638 Completed University Medical Center Groningen 2015-01-31
NCT01014065 A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients (SUnitinib Prospective CardiovasculaR Effect) https://ClinicalTrials.gov/show/NCT01014065 Completed AHS Cancer Control Alberta 2012-11-30
NCT01012011 Regulatory Post Marketing Surveillance Study on Nexavar® https://ClinicalTrials.gov/show/NCT01012011 Completed Bayer 2015-01-31
NCT00980213 Evaluation of the Cost and Effectiveness Sunitinib Compared to Interferon-Alfa in Finland https://ClinicalTrials.gov/show/NCT00980213 Completed Tampere University Hospital 2013-11-30
NCT00979381 Study of the Immunoresponse in Patients Treated With a Tyrosine Kinase Inhibitor https://ClinicalTrials.gov/show/NCT00979381 Completed Radboud University 2008-11-30
NCT00979329 Study on the Influence of Sunitinib and Sorafenib on Fatigue, QoL, Depression in Patients With Metastatic RCC or GIST https://ClinicalTrials.gov/show/NCT00979329 Completed Radboud University 2011-12-31
NCT00927043 Study Evaluating Renal Cell Carcinoma Risk Factors https://ClinicalTrials.gov/show/NCT00927043 Completed Pfizer 2011-09-30
NCT00918775 Follow-up After Metastasectomy in Patients With Kidney Cancer https://ClinicalTrials.gov/show/NCT00918775 Active, not recruiting M.D. Anderson Cancer Center 2020-12-20
NCT00900536 DNA Analysis of Blood and/or Tissue Samples From Patients With Primary Kidney Cancer Receiving Sorafenib on Clinical Trial MRC-RE05-SORCE https://ClinicalTrials.gov/show/NCT00900536 Completed National Cancer Institute (NCI) NA
NCT00900276 Biomarkers in Patients With Kidney Cancer or Cancer of the Urothelium and in Healthy Participants https://ClinicalTrials.gov/show/NCT00900276 Completed Wake Forest University Health Sciences 2011-04-30
NCT00900042 SWOG-9023, DNA Analysis of Tumor Tissue From Patients With Metastatic Kidney Cancer https://ClinicalTrials.gov/show/NCT00900042 Completed Southwest Oncology Group 2002-12-31
NCT00895674 Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment With Nexavar https://ClinicalTrials.gov/show/NCT00895674 Completed Bayer 2010-08-31
NCT00876382 Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT00876382 Completed SCRI Development Innovations, LLC 2011-02-28
NCT00873210 Study In Patients With Kidney Cancer Treated With Sutent https://ClinicalTrials.gov/show/NCT00873210 Completed Pfizer 2011-11-30
NCT00842790 Impact of Predicting Anti-angiogenic Response in mRCC Using Functional Imaging https://ClinicalTrials.gov/show/NCT00842790 Completed Assistance Publique - Hôpitaux de Paris 2014-07-31
NCT03419572 Non-interventional Study of Cabozantinib in Adults With Advanced Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT03419572 Recruiting Ipsen 2021-01-05
NCT00836745 Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent https://ClinicalTrials.gov/show/NCT00836745 Completed Pfizer 2012-07-31
NCT00831857 VEGF Imaging in Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT00831857 Completed University Medical Center Groningen 2011-09-30
NCT04295174 KIDSTAGE- Staging of Kidney Cancer Using Dual Time PET/CT and Other Biomarkers https://ClinicalTrials.gov/show/NCT04295174 Completed Odense University Hospital 2020-01-01
NCT01982097 Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT01982097 Completed Bayer 2017-01-31
NCT01557127 Nexavar Dosing in Renal Cancer Patients in “Real-life” Setting https://ClinicalTrials.gov/show/NCT01557127 Completed Bayer 2014-05-16
NCT00806650 Anti-IMP3 Autoantibody and MicroRNA Signature Blood Tests in Finding Metastasis in Patients With Localized or Metastatic Kidney Cancer https://ClinicalTrials.gov/show/NCT00806650 Completed City of Hope Medical Center 2017-11-15
NCT01411423 Nexavar Post-marketing Surveillance for Renal Cell Carcinoma in Japan https://ClinicalTrials.gov/show/NCT01411423 Completed Bayer 2012-03-16
NCT02282579 Spanish Retrospective Study to Evaluate the Efficacy and Safety of Targeted Therapies After Pazopanib as First-line Therapy https://ClinicalTrials.gov/show/NCT02282579 Completed Spanish Oncology Genito-Urinary Group 2015-02-28
NCT02533258 Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice https://ClinicalTrials.gov/show/NCT02533258 Completed Pfizer 2016-05-12
NCT01934452 Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients https://ClinicalTrials.gov/show/NCT01934452 Recruiting Pfizer 2021-12-01
NCT04005183 Renal Cell Carcinoma Microenvironment Discovery Project https://ClinicalTrials.gov/show/NCT04005183 Recruiting University Health Network, Toronto 2030-05-01
NCT00771147 A Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar ® https://ClinicalTrials.gov/show/NCT00771147 Completed Bayer NA
NCT00743054 microRNA Expression in Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT00743054 Completed Sun Yat-sen University 2009-08-31
NCT00718367 Correlation of the Clinical Behaviour of Renal Cell Carcinoma (RCC) After Debulking Nephrectomy With Tumor Gene Expression in Nephrectomy Specimens https://ClinicalTrials.gov/show/NCT00718367 Completed National University Hospital, Singapore NA
NCT00716625 Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan) https://ClinicalTrials.gov/show/NCT00716625 Completed Pfizer 2015-10-31
NCT00700258 Registry For Temsirolimus, Sunitinib, And Axitinib Treated Patients With Metastatic Renal Cell Carcinoma (mRCC), Mantle Cell Lymphoma (MCL), And Gastro-Intestinal Stroma Tumor (GIST) [STAR-TOR] https://ClinicalTrials.gov/show/NCT00700258 Recruiting Pfizer 2023-12-01
NCT00684645 Non-Interventional Study (NIS) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT® https://ClinicalTrials.gov/show/NCT00684645 Completed Pfizer 2011-04-30
NCT00656955 Follow-Up Study of Kidney Cancer Patients https://ClinicalTrials.gov/show/NCT00656955 Completed National Institutes of Health Clinical Center (CC) 2013-05-31
NCT00617799 Biomarkers That Predict Response to High-Dose Aldesleukin in Patients With Metastatic Kidney Cancer or Metastatic Melanoma https://ClinicalTrials.gov/show/NCT00617799 Completed University of Nebraska 2009-02-18
NCT00513175 Non-Myeloablative Allogeneic Stem Cell Transplantation With Matched Unrelated Donors for Treatment of Hematologic Malignancies, Renal Cell Carcinoma, and Aplastic Anemia https://ClinicalTrials.gov/show/NCT00513175 Completed University of California, San Francisco NA
NCT00509704 Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT00509704 Completed Radboud University NA
NCT00460798 SUTENT® In The First Line Treatment Of Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT00460798 Completed Pfizer 2009-09-30
NCT00340457 Case-Control Study of Renal Cell Cancer Among Caucasions and African Americans in the United States https://ClinicalTrials.gov/show/NCT00340457 Completed National Institutes of Health Clinical Center (CC) NA
NCT00216801 Relationship of Ochratoxin A to Upper Urologic Cancers https://ClinicalTrials.gov/show/NCT00216801 Completed Lawson Health Research Institute 2007-04-30
NCT00026663 Collection of Blood, Bone Marrow, Tumor, or Tissue Samples From Patients With Cancer to Study Drug Resistance https://ClinicalTrials.gov/show/NCT00026663 Recruiting National Institutes of Health Clinical Center (CC) NA
NCT00717743 T Regulatory Cells in Renal Cell Carcinoma (PILOT STUDY) https://ClinicalTrials.gov/show/NCT00717743 Completed National University Hospital, Singapore NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT03374267 Registry Platform Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT03374267 Recruiting iOMEDICO AG 2024-12-31
NCT02325921 MRI in Renal Tumors https://ClinicalTrials.gov/show/NCT02325921 Completed Radboud University 2018-06-30
NCT04197414 Development of Urologic Registry for Personalized Medicine in Patients With Urological Malignancy by Analyzing Circulating Tumor DNA https://ClinicalTrials.gov/show/NCT04197414 Recruiting Yonsei University 2029-11-30
NCT03955393 FAZA PET IMAGING IN DETECTING LYMPH NODE METASTASES IN RENAL CELL CARCINOMA PATIENTS https://ClinicalTrials.gov/show/NCT03955393 Active, not recruiting IRCCS San Raffaele 2019-04-30
NCT03857373 Renal Cancer Detection Using Convolutional Neural Networks https://ClinicalTrials.gov/show/NCT03857373 Recruiting Zealand University Hospital 2023-01-01
NCT03749980 MyVHL: Patient Natural History Study https://ClinicalTrials.gov/show/NCT03749980 Recruiting VHL Alliance 2024-12-31
NCT03630536 TFE Renal Cell Carcinoma: A Prospective Registry and Translational Research Initiative https://ClinicalTrials.gov/show/NCT03630536 Recruiting Children’s Hospital Medical Center, Cincinnati 2028-05-31
NCT03616951 Improved Assessment of Response in Metastatic Renal Cell Carcinoma Using Spectral-CT https://ClinicalTrials.gov/show/NCT03616951 Recruiting University of Aarhus 2023-01-01
NCT03667885 Non-Invasive Diagnostics of Small Renal Masses https://ClinicalTrials.gov/show/NCT03667885 Recruiting Odense University Hospital 2020-01-31
NCT02789137 Study On Fatigue- And Hand-Foot Syndrome-Related Quality Of Life In Patients With Metastatic Renal Cell Carcinoma Receiving A Tyrosine Kinase Inhibitor as First-Line Treatment https://ClinicalTrials.gov/show/NCT02789137 Active, not recruiting Pfizer 2020-09-30
NCT03452774 SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry https://ClinicalTrials.gov/show/NCT03452774 Recruiting Massive Bio, Inc. 2021-12-31
NCT00610012 Tumor Registry of Advanced Renal Cell Carcinoma https://ClinicalTrials.gov/show/NCT00610012 Completed iOMEDICO AG 2020-05-15